Real-world genetic testing data of ovarian cancer patients: Informing counseling in older women

P/LP variant prevalence in ovarian cancer patients ≥70 years, underrepresented in guidelines and clinical trials

Older women with ovarian cancer (≥70 years) are underrepresented in hereditary genetics studies, and clinical guidelines are primarily based on younger cohorts. This real-world study characterizes P/LP variant prevalence and type in these patients, showing significant frequencies of BRCA1/2 and other predisposition gene variants. These data have direct implications for surveillance recommendations and therapeutic decisions (PARP inhibitor maintenance) in older women diagnosed with ovarian cancer.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Age should not be an exclusion criterion for genetic testing in ovarian oncology — PARP inhibitors have demonstrated efficacy regardless of age in BRCA carriers. These real-world data in an elderly population strengthen the argument for universal genetic testing of ovarian cancers without age restriction.

Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 1/1 → Total: 7/10